US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Corgi NVO 2x Daily ETF

13.82

-0.4236-2.97%

Post-market: 13.820.00000.00%16:10 EDT

Volume:16

Turnover:225

Market Cap:207.35K

PE:- -

High:13.82

Open:14.25

Low:13.82

Close:14.25

52wk High:27.19

52wk Low:13.82

Shares:15.00K

Float Shares:15.00K

Volume Ratio:0.12

T/O Rate:0.11%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

23% Weight Loss, 27% Dropouts: How Strong Is Lilly's Phase 2 Combo, Really?

Options & Short Sell

The Next Frontier for Obesity Drugs Isn't How Much Weight You Lose, but What Kind

Moderately bullish activity in Novo Nordisk with shares down 1.06%

Novo Nordisk Opens a New Front in Cardiometabolic Care With Early-Stage Anti-Inflammatory Study

Novo Nordisk Tests Cagrisema Switch Strategy to Strengthen Its Diabetes Franchise

Novo Nordisk A/S Series B Stock Rises Wednesday, Outperforms Market

Weight-Loss Drug Developers Line up to Tap Lucrative Market as Competition Heats Up

Novo Nordisk announces new data on CagriSema

Patients Switching to Novo Nordisk's Wegovy Pill from Shots Lose More Weight in Real-World Study

2026 Nobel Prize Preview: Scientists Behind GLP-1 Weight-Loss Drugs Emerge as Leading Contenders

Novo Says Ozempic Cuts Risk of Major Cardiovascular Events

Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NVO), ClearPoint Neuro (CLPT) and Axsome Therapeutics (AXSM)

Eli Lilly Reports Zepbound Showed 4.5% Greater Weight Loss Than Novo Nordisk's Wegovy HD

MT Newswires Live

Lilly's Zepbound (Tirzepatide 10 Mg and 15 Mg) was Associated with More Weight Loss than Wegovy Hd (Semaglutide Injection 7.2 Mg) in a New Indirect Treatment Comparison

THOMSON REUTERS

Novo Nordisk Says Ozempic Shows Lower Risk of Cardiovascular Events Compared to Eli Lilly's Mounjaro

Novo Nordisk announces retrospective RWE on Ozempic in type 2 diabets

Novo Nordisk Strikes Second Licensing Deal Since Frosty Capital-Markets Day

China's Hengrui Inks up to $2.6 Billion Deal with Novo Nordisk for Obesity Drug

Hengrui Pharma and Novo Nordisk Sign Licensing Agreement for HRS-1596 Project

Option traders moderately bearish in Novo Nordisk with shares down 0.22%

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/NVOC/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NVOC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVOC\",,,,,undefined,":{"symbol":"NVOC","market":"US","secType":"STK","nameCN":"Corgi NVO 2x Daily ETF","latestPrice":13.8235,"timestamp":1790884800000,"preClose":14.2471,"halted":0,"volume":16,"hourTrading":{"tag":"盘后","latestPrice":13.8235,"preClose":13.8235,"latestTime":"16:10 EDT","volume":6,"amount":82.941,"timestamp":1790885404179,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.029732366586884378,"floatShares":15000,"shares":15000,"eps":0,"marketStatus":"Post-Mkt","change":-0.4236,"latestTime":"10-01 16:19:55 EDT","open":14.2471,"high":13.8235,"low":13.8235,"amount":225,"amplitude":0,"askPrice":21.06,"askSize":200,"bidPrice":12.35,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1790899200000},"marketStatusCode":4,"adr":0,"listingDate":1784001600000,"exchange":"CBOE","adjPreClose":14.2471,"nav":14.51,"aum":217650,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":13.8235,"preClose":13.8235,"latestTime":"16:10 EDT","volume":6,"amount":82.941,"timestamp":1790885404179,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.119225},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVOC\",,,,,undefined,":{"symbol":"NVOC","floatShares":15000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.119225,"shares":15000,"dividePrice":0,"high":13.8235,"amplitude":0,"preClose":14.2471,"low":13.8235,"week52Low":13.8235,"pbRate":"--","week52High":27.1863,"institutionHeld":0,"latestPrice":13.8235,"committee":-0.333333,"eps":0,"divideRate":0,"volume":16,"delay":0,"ttmEps":0,"open":14.2471,"prevYearClose":24.92,"prevWeekClose":14.9092,"prevMonthClose":14.2471,"prevQuarterClose":14.2471,"fiveDayClose":14.7609,"twentyDayClose":22.1496},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NVOC\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NVOC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NVOC\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NVOC\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1198490653","title":"23% Weight Loss, 27% Dropouts: How Strong Is Lilly's Phase 2 Combo, Really?","url":"https://stock-news.laohu8.com/highlight/detail?id=1198490653","media":"Options & Short Sell","labels":[],"top":1,"itemType":null,"share":"https://ttm.financial/m/news/1198490653?lang=en_us&edition=fundamental","pubTime":"2026-10-01 07:58","pubTimestamp":1790812717,"startTime":"0","endTime":"0","summary":"","market":"us","thumbnail":"https://static.tigerbbs.com/8818ec487bcc6265f08776aa6beddf07","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/8818ec487bcc6265f08776aa6beddf07"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"23% Weight Loss, 27% Dropouts: How Strong Is Lilly's Phase 2 Combo, Really?","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GPCR","LLY","LLYX","LLII","NVOX","AMGN","ELIL","VKTX","NVOH","RHHBY","NVO","ELIS","NVOC","PFE"],"isVideo":true,"video":{"duration":153,"video_url":"https://news-video-sg.skytigris.cn/videos/remotion/2943/render_2943_1790812083911.mp4","video_thumbnail":"https://community-static.tradeup.com/news/b064c13057afaef2771b273441eaa207","audio_url":"https://news-video-sg.skytigris.cn/videos/remotion/2943/tts/voiceover_61d6040c80e6655f.mp3","isAI":true},"gpt_icon":0},{"id":"2672273391","title":"The Next Frontier for Obesity Drugs Isn't How Much Weight You Lose, but What Kind","url":"https://stock-news.laohu8.com/highlight/detail?id=2672273391","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672273391?lang=en_us&edition=fundamental","pubTime":"2026-10-01 08:00","pubTimestamp":1790812800,"startTime":"0","endTime":"0","summary":"For as long as drugmakers have been testing weight-loss drugs, the question has been: How much weight do people lose?Now it is changing to: What kind of weight are they losing?","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999015978.USD","LU0882574139.USD","LU1623119135.USD","LU0471298694.HKD","LU2112291526.USD","LU1868836757.USD","LU2756315664.SGD","LU2361045086.USD","MEDI","SG9999018865.SGD","BK4532","VHT","IE0004445015.USD","LU2168564149.EUR","IE00B775H168.HKD","LU2023250330.USD","LU0058720904.USD","BK4599","BK4007","IE00BWXC8680.SGD","LU2552382132.HKD","LU2491050154.USD","LU0345770308.USD","LU1023059063.AUD","LU1127390331.HKD","LU2602419157.SGD","LU2491049909.HKD","LU1291159041.SGD","LU0266013472.USD","LU2362541273.HKD","TBXU","LU2237443382.USD","LU1979441026.SGD","LU0640476718.USD","SGXZ99366536.SGD","LU0133085943.USD","LU2168564495.EUR","LU2491050071.SGD","IE00BJJMRY28.SGD","IXJ","LLYX","LU0094547139.USD","NVOH","SG9999018857.SGD","BK4581","LLY","LU1868836914.USD","FHLC","LU2237443978.SGD","LU0256863902.USD","LU0820562030.AUD","LU1551013425.SGD","LU1551013342.USD","SGXZ57979304.SGD","ELIL","LU1868837300.USD","LU0210536198.USD","BK4585","LU1057294990.SGD","LLYZ","LU0456855351.SGD","LU0320765059.SGD","LU0964807845.USD","IE00BN29S564.USD","IE0005OL40V9.USD","LU0889565916.HKD","LU2461242641.AUD","LU1988902786.USD","LU2023251221.USD","IE00BJJMRZ35.SGD","IE0002141913.USD","LU0354030438.USD","LU2111349929.HKD","IE00B4JS1V06.HKD","LU0354030511.USD","LU2462157665.USD","LU1917777945.USD","LU2237443549.SGD","LU2168563687.JPY","LU0006306889.USD","LU0882574055.USD","ILDR","LU0683600562.USD","LU1323610961.USD","LU2271345857.HKD","BK4534","BK4139","LU0203202063.USD","LU1814569148.SGD","SG9999017495.SGD","LU2471134523.USD","LU0316494557.USD","THNR","LU0823416689.USD","LU1720051017.SGD","HRTS","IE00BJT1NW94.SGD","LU0158827781.USD","LU0689472784.USD","LU2168564065.EUR","LU2471134952.CNY","RXL","BK4588","LU0238689110.USD","LU2023250504.SGD","LU2237443622.USD","MEDX","SG9999015945.SGD","LU1720051108.HKD","IE00B2B36J28.USD","IE00BJJMRX11.SGD","LU2108987350.USD","LU2237443465.HKD","LU2063271972.USD","XLV","LU0234572021.USD","LU1983299246.USD","CANC","IE00BFTCPJ56.SGD","LU1232071149.USD","IE00BK4W5L77.USD","REGN","BK4533","LU2552382058.USD","LU2361044865.SGD","BBH","IE00B4R5TH58.HKD","LU1093756168.USD","LU2362540622.SGD","LU2456880835.USD","LU0158827948.USD","LU0114720955.EUR","LU0154236417.USD","LU0256863811.USD","IE0001KFT4U8.USD","LU0823434583.USD","LU0289739699.SGD","LU0385154629.USD","FTXH","IE00BK4W5M84.HKD","LU1280957306.USD","IE00BKDWB100.SGD","IE00BFSS7M15.SGD","IE00B1BXHZ80.USD","LU2552382215.SGD","LU1548497426.USD","IE00BFSS8Q28.SGD","ELIS","LU0417517546.SGD","LU0820561909.HKD","NVOC","JDOC","OZEM","LU1629891620.HKD","LU1868837136.USD","LU2237443895.HKD","SG9999015986.USD","LU1974910355.USD","LU0109394709.USD","LU0943347566.SGD","LU2237438978.USD","TMED","IE00BJLML261.HKD","LU1804176565.USD","LU2896262040.SGD","LU0820561818.USD","LU2168564222.USD","SG9999014880.SGD","LU2746668461.USD","LU2213496289.HKD","LU2211815571.USD","IE00B7KXQ091.USD","LU0345770993.USD","LU0823434740.USD","LU2750360997.AUD","LU0320765992.SGD","SG9999001176.SGD","LU2089984988.USD","LU1267930730.SGD","LU1989771016.USD","LU2471134796.USD","LU2471134879.HKD","LU1712237335.SGD","LU2089283258.USD","LU2357305700.SGD","LU1691799644.USD","LU2746668974.SGD","LU0097036916.USD","LU2417539215.USD","LU0225283273.USD","GB00BDT5M118.USD","LU0106261372.USD","NVO","LU1366192091.USD","LU2265009873.SGD","LU2324357040.USD","BK4516","IE0009355771.USD","LU0061475181.USD","LU0323591593.USD","LU1061106388.HKD","LU0466842654.USD","LU2361044949.HKD","PPH","LU2089284900.SGD","SG9999015952.SGD","PJP","LU0109391861.USD","LU0353189680.USD","IBBQ","LU2236285917.USD","LU0432979614.USD","IE00BKPKM429.USD","LU0203201768.USD","IBB","IE00BZ1G4Q59.USD","IE00B1XK9C88.USD","LU0079474960.USD","LU2106854487.HKD","LU2362541513.USD","LU1868836591.USD","LU2756315318.SGD","NVOX","SGXZ81514606.USD","LU0787776722.HKD","LU0471298777.SGD","LU0053666078.USD","SG9999014906.USD","LU2028103732.USD","LU0198837287.USD","LU0786609619.USD","SG9999014914.USD","LU2087625088.SGD","LU0708995401.HKD","AGNG","IE0004445239.USD","LU2360106947.USD","LU1093756325.SGD","IYH","LU0174119429.USD","LU2750360641.GBP","LU2264538146.SGD","SGXZ31699556.SGD","LU0672654240.SGD","TRUH","LU1035775433.USD","LU1069344957.HKD","LU1145028129.USD","LU0353189763.USD","GDOC","CURE","LU1064131342.USD","LU2468319806.SGD","MHIP","LLII","LU0122379950.USD","LU2462591350.SGD","SG9999001176.USD","SG9999013999.USD","SG9999014898.SGD","SGXZ51526630.SGD","WDNA","IE00BKVL7J92.USD","IHE","LU0096364046.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672787943","title":"Moderately bullish activity in Novo Nordisk with shares down 1.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2672787943","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672787943?lang=en_us&edition=fundamental","pubTime":"2026-10-01 04:45","pubTimestamp":1790801124,"startTime":"0","endTime":"0","summary":"Moderately bullish activity in Novo Nordisk (NVO), with shares down 40c near $37.91. Options volume roughly in line with average with 54k contracts...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/moderately-bullish-activity-in-novo-nordisk-with-shares-down-1-06-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/moderately-bullish-activity-in-novo-nordisk-with-shares-down-1-06-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVOC","BK4585","NVO","BK4588","LU1093756325.SGD","PPH","LU0154236417.USD","LU1093756168.USD","OZEM","IE00BZ1G4Q59.USD","NVOX","IE00BKVL7J92.USD","THNR","BK4532","BK4599","BK4007","NVOH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672700786","title":"Novo Nordisk Opens a New Front in Cardiometabolic Care With Early-Stage Anti-Inflammatory Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2672700786","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672700786?lang=en_us&edition=fundamental","pubTime":"2026-10-01 00:31","pubTimestamp":1790785892,"startTime":"0","endTime":"0","summary":"Novo Nordisk ($NVO) announced an update on their ongoing clinical study. Novo Nordisk Explores New Anti-Inflammatory Pathway for Heart and Metaboli...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/novo-nordisk-opens-a-new-front-in-cardiometabolic-care-with-early-stage-anti-inflammatory-study?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/novo-nordisk-opens-a-new-front-in-cardiometabolic-care-with-early-stage-anti-inflammatory-study?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","LU1093756168.USD","OZEM","NVOC","LU0154236417.USD","PPH","BK4588","BK4532","IE00BKVL7J92.USD","NVOH","NVOX","BK4007","THNR","IE00BZ1G4Q59.USD","LU1093756325.SGD","NVO","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672778609","title":"Novo Nordisk Tests Cagrisema Switch Strategy to Strengthen Its Diabetes Franchise","url":"https://stock-news.laohu8.com/highlight/detail?id=2672778609","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672778609?lang=en_us&edition=fundamental","pubTime":"2026-10-01 00:31","pubTimestamp":1790785861,"startTime":"0","endTime":"0","summary":"Novo Nordisk ($NVO) announced an update on their ongoing clinical study. Novo Nordisk Studies Key Switch From Ozempic to Cagrisema for Type 2 Diabe...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/novo-nordisk-tests-cagrisema-switch-strategy-to-strengthen-its-diabetes-franchise?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/novo-nordisk-tests-cagrisema-switch-strategy-to-strengthen-its-diabetes-franchise?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0154236417.USD","BK4532","IE00BKVL7J92.USD","BK4588","BK4585","LU1093756168.USD","NVO","NVOC","BK4007","NVOH","OZEM","THNR","NVOX","LU1093756325.SGD","BK4599","IE00BZ1G4Q59.USD","PPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672597786","title":"Novo Nordisk A/S Series B Stock Rises Wednesday, Outperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2672597786","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672597786?lang=en_us&edition=fundamental","pubTime":"2026-10-01 00:03","pubTimestamp":1790784180,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of Novo Nordisk A/S Series B advanced 0.6% to DKK253.20 Wednesday on what proved to be an overall negative trading session for the stock market, with the OMX Nordic 40 Index falling 0.4% to 2,597.48.The stock's rise  snapped a two-day losing streak.The company closed DKK156.75 short of its 52-week high of DKK409.95, which the company reached on January 23, 2026.Trading volume was 7,931,061, compared to the 50-day average trading volume of 4,771,126.Data source: Dow Jones Market Data, FactSet","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OZEM","BK4599","BK4585","IE00BKVL7J92.USD","LU1093756168.USD","BK4588","NVOC","THNR","LU0154236417.USD","NVOX","PPH","LU1093756325.SGD","NVO","IE00BZ1G4Q59.USD","BK4007","NVOH","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671783524","title":"Weight-Loss Drug Developers Line up to Tap Lucrative Market as Competition Heats Up","url":"https://stock-news.laohu8.com/highlight/detail?id=2671783524","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671783524?lang=en_us&edition=fundamental","pubTime":"2026-09-30 22:45","pubTimestamp":1790779502,"startTime":"0","endTime":"0","summary":"FACTBOX-Weight-loss drug developers line up to tap lucrative market as competition heats upSept 30 (Reuters)-The weight-loss drug market is booming, with biotech firms racing to capture a slice of the","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nL4N45M19G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2168564222.USD","LU2360106947.USD","AGNG","LU2361044865.SGD","SG9999015952.SGD","LU0158827948.USD","LU1291159041.SGD","LU2028103732.USD","LU1720051108.HKD","SG9999015945.SGD","ELIS","LU0154236417.USD","LU0316494557.USD","SG9999018865.SGD","LU1093756168.USD","LU0823434740.USD","LU2087625088.SGD","TMED","LU2491049909.HKD","BK4599","LU1629891620.HKD","LU0353189763.USD","IE00B7KXQ091.USD","LU1623119135.USD","LU2111349929.HKD","LU2756315318.SGD","WDNA","LU0114720955.EUR","LU2089284900.SGD","LU0882574055.USD","LU2471134879.HKD","LU0094547139.USD","LU2106854487.HKD","LU2168564065.EUR","IE00B1BXHZ80.USD","LU1868836591.USD","IE0001KFT4U8.USD","LU2237443382.USD","LU0820561909.HKD","LU0106261372.USD","LU1551013425.SGD","LU2491050071.SGD","LU2471134796.USD","LU1035775433.USD","SG9999017495.SGD","HRTS","LLY","LU0256863902.USD","LU0203201768.USD","LU2168564149.EUR","LU2237443465.HKD","IE00BJJMRX11.SGD","IE00BZ1G4Q59.USD","LU2237438978.USD","LU2461242641.AUD","GB00BDT5M118.USD","LU2468319806.SGD","XLV","LU2236285917.USD","BK4516","IE00BK4W5L77.USD","LU2271345857.HKD","LU2063271972.USD","LU2324357040.USD","LU2602419157.SGD","LU2361044949.HKD","LU2756315664.SGD","LU0964807845.USD","LU2023250504.SGD","IE00BWXC8680.SGD","IE00BFSS8Q28.SGD","LU2089283258.USD","LU1974910355.USD","LU0466842654.USD","IE00BJJMRZ35.SGD","LU0256863811.USD","LU0097036916.USD","LU0345770308.USD","LU0787776722.HKD","LU1057294990.SGD","LU2456880835.USD","LU0234572021.USD","LU1868836914.USD","NVO","SGXZ57979304.SGD","IE00BK4W5M84.HKD","LU1979441026.SGD","IE00BKDWB100.SGD","IHE","LU0943347566.SGD","SG9999014880.SGD","LU0345770993.USD","LU0456855351.SGD","LU0432979614.USD","LU2896262040.SGD","LU0786609619.USD","LU1868836757.USD","LU2112291526.USD","IE0004445239.USD","LU0823416689.USD","BK4533","IE0005OL40V9.USD","LU2237443978.SGD","LU2417539215.USD","NVOH","LU1267930730.SGD","GDOC","LU2471134952.CNY","LU2491050154.USD","LU1868837136.USD","LU1868837300.USD","LU0889565916.HKD","LU0109391861.USD","LU2168564495.EUR","BK4532","LU0109394709.USD","LU1069344957.HKD","LU0061475181.USD","LU0689472784.USD","LU1023059063.AUD","SG9999014906.USD","IE00BN29S564.USD","IE00B4R5TH58.HKD","LU0210536198.USD","LU0320765059.SGD","LU0471298694.HKD","LU1551013342.USD","FHLC","BK4581","LU0058720904.USD","LU0289739699.SGD","MHIP","VHT","IE00BJLML261.HKD","JDOC","LU1804176565.USD","RXL","LU0708995401.HKD","MEDI","LU2108987350.USD","BK4007","LU0266013472.USD","LU0354030438.USD","SG9999001176.USD","SGXZ51526630.SGD","IE00B4JS1V06.HKD","LU0471298777.SGD","LU0122379950.USD","LU2750360997.AUD","LU1064131342.USD","LU1989771016.USD","CURE","IE0004445015.USD","LU0417517546.SGD","BK4588","IE00BFSS7M15.SGD","LU2471134523.USD","LU0096364046.USD","LU0174119429.USD","LU1127390331.HKD","LU1061106388.HKD","LU0320765992.SGD","LU1720051017.SGD","LU2023251221.USD","LU2168563687.JPY","LU2462591350.SGD","TRUH","LU0823434583.USD","LLYZ","IE00BKVL7J92.USD","CANC","LU1983299246.USD","LU2237443622.USD","LU0238689110.USD","ILDR","LU0323591593.USD","IE00BJT1NW94.SGD","LU1093756325.SGD","BK4585","LU0385154629.USD","PJP","FTXH","IYH","LU0006306889.USD","LU2211815571.USD","LU2746668974.SGD","LU0354030511.USD","LU2462157665.USD","LU1712237335.SGD","SG9999014914.USD","LU1232071149.USD","LU2265009873.SGD","LU2746668461.USD","SG9999001176.SGD","LU1917777945.USD","ELIL","SGXZ81514606.USD","LU0198837287.USD","LLYX","SG9999015986.USD","LU2552382215.SGD","LU0225283273.USD","IXJ","SG9999018857.SGD","SGXZ99366536.SGD","IE00B775H168.HKD","LU0158827781.USD","IE00BJJMRY28.SGD","LU0203202063.USD","LU0882574139.USD","LU1548497426.USD","LU2023250330.USD","NVOC","LU1280957306.USD","LU1691799644.USD","THNR","BK4534","LU0133085943.USD","LU0640476718.USD","LU2361045086.USD","SGXZ31699556.SGD","NVOX","LU0820561818.USD","IE00BFTCPJ56.SGD","LU0079474960.USD","LU1814569148.SGD","SG9999014898.SGD","LU0353189680.USD","LU0683600562.USD","LU2089984988.USD","IE0009355771.USD","IE00B2B36J28.USD","IE0002141913.USD","LU1366192091.USD","SG9999013999.USD","LU2237443895.HKD","LU1145028129.USD","LU2264538146.SGD","LU2237443549.SGD","LU2357305700.SGD","LLII","LU2750360641.GBP","OZEM","IE00BKPKM429.USD","PPH","IE00B1XK9C88.USD","LU2213496289.HKD","LU2552382132.HKD","LU2552382058.USD","LU1988902786.USD","LU1323610961.USD","MEDX","SG9999015978.USD","LU0672654240.SGD","LU0820562030.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671202417","title":"Novo Nordisk announces new data on CagriSema","url":"https://stock-news.laohu8.com/highlight/detail?id=2671202417","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671202417?lang=en_us&edition=fundamental","pubTime":"2026-09-30 20:46","pubTimestamp":1790772380,"startTime":"0","endTime":"0","summary":"The company states: “Novo Nordisk (NVO) announced new data on how CagriSema works inside both the brain and body, presented at the European Associa...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novo-nordisk-announces-new-data-on-cagrisema-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novo-nordisk-announces-new-data-on-cagrisema-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4588","BK4585","NVOX","PPH","IE00BKVL7J92.USD","BK4532","IE00BZ1G4Q59.USD","BK4599","NVO","NVOC","NVOH","THNR","LU1093756325.SGD","LU1093756168.USD","OZEM","LU0154236417.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671270754","title":"Patients Switching to Novo Nordisk's Wegovy Pill from Shots Lose More Weight in Real-World Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2671270754","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671270754?lang=en_us&edition=fundamental","pubTime":"2026-09-30 17:45","pubTimestamp":1790761500,"startTime":"0","endTime":"0","summary":"Patients switching toNovo Nordisk's Wegovy pill from shots lose more weight in real-world studySept 30 -Patients who switched from weight-loss injections to Novo Nordisk'sNOVOb.COdaily Wegovy pill continued to lose weight, according to data unveiled at a medical meeting on Wednesday, as the Danish drugmaker seeks to defend its lead over US rival Eli LillyLLY.Nin the market for oral obesity treatments.Study participants lost an average of 4.1% of their body weight over three months after transitioning from injectable obesity therapies — including Wegovy and Lilly's Zepbound — to oral semaglutide, the active ingredient in Wegovy, as well as Ozempic.Patients lost an average of 4.0 kg  from a baseline weight of 221.6 pounds  after making the switch, and the proportion of participants classified as clinically obese dropped to 65.5% from 87.1% after three months, with nearly 41% shedding at least 5% of their body weight.\"There's been a lot of questions on can people be compliant to the pill?","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nL6N45L0IH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4599","LU1093756325.SGD","NVO","NVOC","IE00BZ1G4Q59.USD","BK4585","BK4532","BK4007","LU1093756168.USD","NVOH","NVOX","LU0154236417.USD","THNR","IE00BKVL7J92.USD","PPH","BK4588","OZEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176833437","title":"2026 Nobel Prize Preview: Scientists Behind GLP-1 Weight-Loss Drugs Emerge as Leading Contenders","url":"https://stock-news.laohu8.com/highlight/detail?id=1176833437","media":"Deep News","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176833437?lang=en_us&edition=fundamental","pubTime":"2026-09-30 16:00","pubTimestamp":1790755226,"startTime":"0","endTime":"0","summary":"The 2026 Nobel Prize laureates will be announced successively from October 5 to 12. In order to understand the list of hot candidates, The Scientist published scientists' predictions for the 2026...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELIL","XLVI","PINK","TRUH","LLYX","LLII","NVOX","JDOC","ELIS","FHLC","THNR","IYH","CURE","NVOH","FXH","PJP","RSPH","NVOC","MEDI","NBDS","OZEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671321075","title":"Novo Says Ozempic Cuts Risk of Major Cardiovascular Events","url":"https://stock-news.laohu8.com/highlight/detail?id=2671321075","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671321075?lang=en_us&edition=fundamental","pubTime":"2026-09-29 22:13","pubTimestamp":1790691203,"startTime":"0","endTime":"0","summary":"BRIEF-Novo Says Ozempic Cuts Risk Of Major Cardiovascular EventsSept 29 (Reuters)-Novo Nordisk A/SNOVOb.CO:NOVO'S OZEMPIC (SEMAGLUTIDE) 2 MG ASSOCIATED WITH LOWER RISK OF MAJOR ADVERSE CARDIOVASCULAR ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nFWN45K15E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00BZ1G4Q59.USD","LU1093756168.USD","NVO","LU0154236417.USD","NVOX","BK4585","PPH","OZEM","BK4007","LU1093756325.SGD","THNR","NVOH","BK4532","BK4599","IE00BKVL7J92.USD","NVOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671210199","title":"Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NVO), ClearPoint Neuro (CLPT) and Axsome Therapeutics (AXSM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2671210199","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671210199?lang=en_us&edition=fundamental","pubTime":"2026-09-29 21:40","pubTimestamp":1790689233,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Novo Nordisk (NVO), ClearPoint Neuro (CLPT) and Ax...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-novo-nordisk-nvo-clearpoint-neuro-clpt-and-axsome-therapeutics-axsm-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-novo-nordisk-nvo-clearpoint-neuro-clpt-and-axsome-therapeutics-axsm-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1093756168.USD","BK4585","PPH","BK4532","CLPT","NVOX","BK4082","LU0154236417.USD","AXSM","BK4007","NVOH","NVOC","LU1093756325.SGD","NVO","BK4505","BK4599","THNR","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","OZEM","BK4588","LU2324357040.USD","PTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671211626","title":"Eli Lilly Reports Zepbound Showed 4.5% Greater Weight Loss Than Novo Nordisk's Wegovy HD","url":"https://stock-news.laohu8.com/highlight/detail?id=2671211626","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671211626?lang=en_us&edition=fundamental","pubTime":"2026-09-29 20:02","pubTimestamp":1790683358,"startTime":"0","endTime":"0","summary":"Eli Lilly  said Tuesday that a new indirect analysis showed its drug Zepbound produced 4.5% greater weight loss than Novo Nordisk's  Wegovy HD in adults with obesity.The analysis compared data from the SURMOUNT-1 and STEP UP trials, according to the company.Patients taking a 15-milligram dose of Zepbound achieved the 4.5% greater average weight reduction over 72 weeks, the company said.Participants receiving a 10-milligram dose of the medication lost 3.2% more of their body weight on average compared with those on Wegovy HD, it said.Those taking the highest Zepbound dose were more than three times as likely to achieve at least a 20% reduction in body weight, and discontinuation rates due to adverse events were comparable across both treatments, Eli Lilly said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0889565916.HKD","IE00B4R5TH58.HKD","MEDX","LU2264538146.SGD","IE00BJJMRX11.SGD","LU2750360641.GBP","LLYX","LU1623119135.USD","LU2023250330.USD","LLII","LU0820561909.HKD","LU2361044865.SGD","SGXZ57979304.SGD","CANC","LU0466842654.USD","SG9999015952.SGD","LU1988902786.USD","LU2168564222.USD","LU2361044949.HKD","LU0708995401.HKD","LU1232071149.USD","IYH","LU0943347566.SGD","SG9999001176.SGD","SG9999015978.USD","BK4007","LU2106854487.HKD","IE00BZ1G4Q59.USD","TMED","IE00B4JS1V06.HKD","LU2237443382.USD","IE00B2B36J28.USD","LU0256863902.USD","LU1057294990.SGD","LU1064131342.USD","LU1989771016.USD","LU2471134523.USD","LU2552382132.HKD","LU1868836591.USD","JDOC","IE00BK4W5M84.HKD","IE00BKDWB100.SGD","LU0882574139.USD","LU2462591350.SGD","LU0061475181.USD","SGXZ51526630.SGD","LU0823434740.USD","WDNA","LU2063271972.USD","SG9999014906.USD","LU2237443465.HKD","LU2471134952.CNY","LU1868837136.USD","THNR","LU2750360997.AUD","IE00BN29S564.USD","SG9999017495.SGD","LU0097036916.USD","LU2417539215.USD","BK4533","LU1093756168.USD","LU2361045086.USD","IE00BKVL7J92.USD","PPH","LU0353189680.USD","IE00BJJMRY28.SGD","LU0354030511.USD","NVOH","LU0106261372.USD","LU0238689110.USD","OZEM","LU1023059063.AUD","LU2471134879.HKD","ELIL","IE0002141913.USD","IE00BFTCPJ56.SGD","LU0964807845.USD","BK4599","LU0683600562.USD","LU0432979614.USD","IE00BWXC8680.SGD","LU1720051017.SGD","LU0820562030.AUD","LU1868837300.USD","LU2456880835.USD","LU0225283273.USD","IE0004445239.USD","LU2491050154.USD","LU2552382058.USD","FHLC","LU1291159041.SGD","LU2471134796.USD","BK4516","LU1551013425.SGD","LU2357305700.SGD","LU1868836757.USD","LU2111349929.HKD","LU2087625088.SGD","LU2168564495.EUR","LU0640476718.USD","LU0094547139.USD","LU1127390331.HKD","LU2265009873.SGD","LU2237443622.USD","IE0009355771.USD","LU0154236417.USD","LU2746668461.USD","LU2896262040.SGD","ELIS","IE00BFSS8Q28.SGD","LU2756315664.SGD","TRUH","LU2023251221.USD","LU0320765992.SGD","LU0323591593.USD","IE0001KFT4U8.USD","SG9999014914.USD","LU1280957306.USD","LU2462157665.USD","LU2089984988.USD","LU2168564149.EUR","CURE","IXJ","LU1035775433.USD","LU0689472784.USD","IE0004445015.USD","LU2756315318.SGD","LU2237443895.HKD","SG9999001176.USD","LU0234572021.USD","LU2552382215.SGD","LU1917777945.USD","LU0174119429.USD","LU0096364046.USD","LU2236285917.USD","LU1868836914.USD","LU2237443978.SGD","LU0471298694.HKD","LU0385154629.USD","LU0823416689.USD","MEDI","SG9999018865.SGD","LU0203201768.USD","LU0256863811.USD","LU0786609619.USD","LU2213496289.HKD","IE00B7KXQ091.USD","LU1551013342.USD","LU1629891620.HKD","LU0109391861.USD","LU1691799644.USD","LU1712237335.SGD","SG9999013999.USD","LU0158827948.USD","LU0820561818.USD","LU1061106388.HKD","LU0058720904.USD","LU0353189763.USD","LU0354030438.USD","MHIP","HRTS","LU0456855351.SGD","LU1814569148.SGD","LU1093756325.SGD","LU2237443549.SGD","XLV","LU1979441026.SGD","LU1974910355.USD","LU0133085943.USD","RXL","LU2168563687.JPY","LU1323610961.USD","LU1366192091.USD","SG9999014880.SGD","LU0203202063.USD","LU0471298777.SGD","GB00BDT5M118.USD","LU2491049909.HKD","LU0823434583.USD","BK4585","IE00BJT1NW94.SGD","LU0266013472.USD","NVOC","SG9999015986.USD","IE00BK4W5L77.USD","LU2360106947.USD","ILDR","LU1267930730.SGD","IHE","LU0006306889.USD","LU2108987350.USD","LU2089284900.SGD","LU0122379950.USD","LU2237438978.USD","LU2324357040.USD","IE00B1XK9C88.USD","LU0787776722.HKD","LU2468319806.SGD","GDOC","LU1069344957.HKD","LU1548497426.USD","LU2271345857.HKD","LU2602419157.SGD","LU2461242641.AUD","LU0289739699.SGD","NVO","LU2746668974.SGD","SGXZ31699556.SGD","LU0672654240.SGD","IE00BFSS7M15.SGD","LU0882574055.USD","IE00BJLML261.HKD","IE00BJJMRZ35.SGD","LU1804176565.USD","FTXH","LU2112291526.USD","IE00B775H168.HKD","LU2023250504.SGD","SG9999018857.SGD","IE00BKPKM429.USD","IE00B1BXHZ80.USD","LU2211815571.USD","LU0079474960.USD","IE0005OL40V9.USD","LU1720051108.HKD","LU0345770993.USD","PJP","BK4588","LU0210536198.USD","LU0417517546.SGD","LU0158827781.USD","LU2028103732.USD","NVOX","LU1983299246.USD","SGXZ99366536.SGD","LU2089283258.USD","SG9999015945.SGD","BK4532","VHT","LU0345770308.USD","LU1145028129.USD","AGNG","SG9999014898.SGD","SGXZ81514606.USD","LU0316494557.USD","LU0109394709.USD","LLY","BK4581","LLYZ","LU0114720955.EUR","LU0320765059.SGD","LU2491050071.SGD","LU0198837287.USD","LU2168564065.EUR","BK4534"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671215761","title":"Lilly's Zepbound (Tirzepatide 10 Mg and 15 Mg) was Associated with More Weight Loss than Wegovy Hd (Semaglutide Injection 7.2 Mg) in a New Indirect Treatment Comparison","url":"https://stock-news.laohu8.com/highlight/detail?id=2671215761","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671215761?lang=en_us&edition=fundamental","pubTime":"2026-09-29 19:00","pubTimestamp":1790679602,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nTUA7RLVWP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["WDNA","LU0708995401.HKD","LU2087625088.SGD","GB00BDT5M118.USD","LU1712237335.SGD","LU0964807845.USD","LU1629891620.HKD","SGXZ57979304.SGD","LU1868837136.USD","SGXZ81514606.USD","LU0345770308.USD","SG9999001176.SGD","LU1291159041.SGD","LU2746668461.USD","LU0385154629.USD","MHIP","SG9999014906.USD","LU1804176565.USD","LU2471134879.HKD","LU2168563687.JPY","RXL","SGXZ31699556.SGD","IE00B775H168.HKD","LU0114720955.EUR","LU0471298694.HKD","LU2237443978.SGD","LU2324357040.USD","LU0154236417.USD","LU1093756325.SGD","LU2265009873.SGD","LU2417539215.USD","LU1548497426.USD","LU1064131342.USD","LU2361044865.SGD","BK4588","XLV","LU2108987350.USD","BK4516","LU0466842654.USD","LU2360106947.USD","BK4532","LU0882574055.USD","PPH","PJP","LU1145028129.USD","IE0002141913.USD","LU2237443549.SGD","FTXH","LU0210536198.USD","LU2491049909.HKD","LU2756315664.SGD","IE00BKDWB100.SGD","LU2089284900.SGD","VHT","IE0009355771.USD","IE00BJJMRX11.SGD","IE00BK4W5M84.HKD","LU2023250504.SGD","LU0943347566.SGD","LU2213496289.HKD","LU2602419157.SGD","SG9999015945.SGD","BK4585","IE00BKVL7J92.USD","BK4581","LLY","SG9999014880.SGD","ELIS","LU0823416689.USD","LU1551013342.USD","SG9999013999.USD","GDOC","LLYX","LU0058720904.USD","IE00BJLML261.HKD","LU0471298777.SGD","LU2023251221.USD","BK4534","LU0109391861.USD","LU0456855351.SGD","LU1057294990.SGD","LU0109394709.USD","LU1061106388.HKD","LU2896262040.SGD","LU1868836591.USD","LU2491050154.USD","LU2361045086.USD","LU0417517546.SGD","LU0234572021.USD","LU0203202063.USD","LU0133085943.USD","LU0323591593.USD","LU2236285917.USD","LU1323610961.USD","MEDX","LU2168564222.USD","LU0106261372.USD","ILDR","IE0001KFT4U8.USD","LU1280957306.USD","LU2111349929.HKD","LU0097036916.USD","LU1979441026.SGD","LU1069344957.HKD","LU2237443382.USD","LU0096364046.USD","LU2750360997.AUD","LU1267930730.SGD","LU2089283258.USD","THNR","IE00BFTCPJ56.SGD","LU0266013472.USD","NVOH","CURE","BK4533","IE00BFSS7M15.SGD","LU0320765059.SGD","LU0158827948.USD","LU0320765992.SGD","HRTS","LU1093756168.USD","TMED","LU2028103732.USD","LU2750360641.GBP","LU1127390331.HKD","LU0238689110.USD","LU2237443465.HKD","LU0354030438.USD","LU1720051017.SGD","LU0345770993.USD","IE0005OL40V9.USD","SG9999015952.SGD","LU1623119135.USD","LLII","LU2468319806.SGD","LU2471134523.USD","SGXZ99366536.SGD","LU1868837300.USD","LU1868836757.USD","LU2237438978.USD","LU2471134952.CNY","LU0289739699.SGD","LU0316494557.USD","MEDI","CANC","LU0158827781.USD","NVOX","LU1974910355.USD","LU1988902786.USD","LU2756315318.SGD","IE00BWXC8680.SGD","LU0079474960.USD","LU2211815571.USD","LU0174119429.USD","LU1917777945.USD","SG9999015978.USD","SGXZ51526630.SGD","IE00B4JS1V06.HKD","IXJ","SG9999001176.USD","SG9999014914.USD","LU0823434583.USD","LU0889565916.HKD","LU2023250330.USD","LU0354030511.USD","LU0820562030.AUD","LU1814569148.SGD","LLYZ","IE00BJT1NW94.SGD","TRUH","LU2456880835.USD","AGNG","LU0689472784.USD","LU2746668974.SGD","LU1035775433.USD","LU0432979614.USD","SG9999014898.SGD","ELIL","IE00B2B36J28.USD","IE00BJJMRY28.SGD","LU0256863902.USD","LU1720051108.HKD","IE00BKPKM429.USD","IE00B1XK9C88.USD","IE00B1BXHZ80.USD","LU0672654240.SGD","NVO","SG9999015986.USD","LU2112291526.USD","LU2063271972.USD","LU2471134796.USD","IE00BK4W5L77.USD","IE00BJJMRZ35.SGD","LU0820561818.USD","IE00B4R5TH58.HKD","LU2271345857.HKD","LU2552382058.USD","LU0353189680.USD","LU0122379950.USD","LU0786609619.USD","LU1691799644.USD","IE0004445015.USD","BK4599","SG9999018865.SGD","LU0256863811.USD","LU2462591350.SGD","JDOC","LU0823434740.USD","SG9999017495.SGD","LU2106854487.HKD","LU0820561909.HKD","LU2089984988.USD","IE00B7KXQ091.USD","LU0225283273.USD","IE00BFSS8Q28.SGD","LU0353189763.USD","LU0882574139.USD","LU1366192091.USD","LU1989771016.USD","LU2168564065.EUR","LU2168564495.EUR","LU0006306889.USD","LU2357305700.SGD","LU2461242641.AUD","IYH","LU2237443895.HKD","LU0787776722.HKD","LU2237443622.USD","IE0004445239.USD","LU1551013425.SGD","LU1868836914.USD","LU1232071149.USD","LU0640476718.USD","IHE","LU0203201768.USD","BK4007","LU0683600562.USD","LU2491050071.SGD","LU2552382215.SGD","OZEM","FHLC","LU0094547139.USD","LU1023059063.AUD","LU2552382132.HKD","LU0061475181.USD","LU1983299246.USD","LU2168564149.EUR","LU2264538146.SGD","NVOC","LU2361044949.HKD","LU2462157665.USD","LU0198837287.USD","IE00BN29S564.USD","IE00BZ1G4Q59.USD","SG9999018857.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671132642","title":"Novo Nordisk Says Ozempic Shows Lower Risk of Cardiovascular Events Compared to Eli Lilly's Mounjaro","url":"https://stock-news.laohu8.com/highlight/detail?id=2671132642","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671132642?lang=en_us&edition=fundamental","pubTime":"2026-09-29 18:28","pubTimestamp":1790677698,"startTime":"0","endTime":"0","summary":"Novo Nordisk says Ozempic shows lower risk of cardiovascular events compared to Eli Lilly's MounjaroCOPENHAGEN, Sept 29 (Reuters)-Novo NordiskNOVOb.COsaid on Tuesday a real-world study found that adul","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nL8N45L0SH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN29S564.USD","LU0174119429.USD","LU1291159041.SGD","LU2896262040.SGD","IXJ","LU2023250504.SGD","LU2023251221.USD","BK4588","IE00BFSS7M15.SGD","LU2111349929.HKD","SG9999015986.USD","LU2237443549.SGD","LU1988902786.USD","LU1548497426.USD","SGXZ81514606.USD","ELIL","LU1551013425.SGD","LU2461242641.AUD","LU1868836914.USD","LU2552382132.HKD","LU0787776722.HKD","BK4516","LU0096364046.USD","LU1868837136.USD","GDOC","LU0154236417.USD","LU2063271972.USD","IE0004445015.USD","SG9999013999.USD","LU0471298777.SGD","LU2271345857.HKD","LU2211815571.USD","LU0109391861.USD","LU0471298694.HKD","LU0820562030.AUD","LU2264538146.SGD","LU2265009873.SGD","LU0061475181.USD","LU1868836591.USD","LU2462157665.USD","IE00BK4W5L77.USD","LU2756315318.SGD","IE0009355771.USD","LLII","LU0238689110.USD","LU1093756168.USD","SGXZ99366536.SGD","LU2471134796.USD","LU1323610961.USD","LU1061106388.HKD","LU0320765992.SGD","LU2237443382.USD","SG9999018865.SGD","LU1366192091.USD","IE00BKPKM429.USD","LU2089283258.USD","LU0354030438.USD","LU2324357040.USD","SG9999018857.SGD","LU2361044865.SGD","GB00BDT5M118.USD","LU0225283273.USD","LU0203202063.USD","LU0210536198.USD","LU1035775433.USD","SGXZ31699556.SGD","LU1145028129.USD","IE00B4R5TH58.HKD","IE00BKVL7J92.USD","BK4532","IE00BFTCPJ56.SGD","LU0106261372.USD","LU0708995401.HKD","LU1720051017.SGD","IE00B775H168.HKD","LU2236285917.USD","WDNA","LU0882574055.USD","LU1064131342.USD","IE00BJLML261.HKD","LU2112291526.USD","LU2491050071.SGD","NVOH","SG9999001176.SGD","LU0345770993.USD","SG9999014898.SGD","ELIS","HRTS","LLY","NVOC","LU0882574139.USD","MEDX","IE0001KFT4U8.USD","LU0114720955.EUR","LU1974910355.USD","LU2602419157.SGD","SG9999001176.USD","BK4533","CANC","LU2471134523.USD","SGXZ51526630.SGD","IE00BJJMRY28.SGD","LU1267930730.SGD","LU0385154629.USD","LU2237443895.HKD","BK4581","LU0823434583.USD","FTXH","LU0158827948.USD","IE00BK4W5M84.HKD","IE00B7KXQ091.USD","LU1712237335.SGD","IE00BZ1G4Q59.USD","SGXZ57979304.SGD","RXL","LLYZ","SG9999015978.USD","LU2028103732.USD","LU0006306889.USD","LU0345770308.USD","IE00B2B36J28.USD","JDOC","LU2023250330.USD","LU2168563687.JPY","LU2417539215.USD","LU2746668461.USD","PPH","LU1989771016.USD","MHIP","LU2468319806.SGD","LU0456855351.SGD","LU2213496289.HKD","LU2361045086.USD","LU0234572021.USD","BK4585","LLYX","ILDR","LU0466842654.USD","LU0079474960.USD","LU1623119135.USD","LU2456880835.USD","AGNG","LU1232071149.USD","LU2087625088.SGD","LU0316494557.USD","LU0353189680.USD","LU0786609619.USD","PJP","SG9999014914.USD","LU2168564222.USD","TRUH","LU0683600562.USD","CURE","LU0823416689.USD","FHLC","LU0266013472.USD","LU0640476718.USD","LU0964807845.USD","IE00BKDWB100.SGD","LU1720051108.HKD","IHE","IE0005OL40V9.USD","LU2089284900.SGD","LU1057294990.SGD","LU2360106947.USD","SG9999017495.SGD","IE00BWXC8680.SGD","LU0133085943.USD","NVO","SG9999014906.USD","BK4007","LU0320765059.SGD","LU0823434740.USD","LU2746668974.SGD","LU0943347566.SGD","LU1093756325.SGD","LU2491049909.HKD","LU2361044949.HKD","LU2108987350.USD","LU0323591593.USD","LU0097036916.USD","LU0198837287.USD","LU0672654240.SGD","IE00BFSS8Q28.SGD","BK4599","LU1069344957.HKD","LU1804176565.USD","LU1868836757.USD","LU2168564495.EUR","LU1551013342.USD","LU2756315664.SGD","LU2168564065.EUR","TMED","LU0203201768.USD","LU0820561818.USD","LU0889565916.HKD","LU0289739699.SGD","IE0004445239.USD","LU1868837300.USD","LU0820561909.HKD","LU2471134952.CNY","LU1691799644.USD","LU0109394709.USD","LU1127390331.HKD","IE00B1BXHZ80.USD","LU0094547139.USD","LU1023059063.AUD","IE00B1XK9C88.USD","SG9999015952.SGD","IE00B4JS1V06.HKD","LU0122379950.USD","LU1983299246.USD","MEDI","LU2750360997.AUD","LU2552382215.SGD","LU1629891620.HKD","NVOX","LU2106854487.HKD","SG9999014880.SGD","XLV","LU2471134879.HKD","LU2552382058.USD","LU0256863811.USD","IYH","LU2237443978.SGD","LU1917777945.USD","LU2750360641.GBP","LU0353189763.USD","LU2237443465.HKD","LU2237438978.USD","LU0417517546.SGD","LU2237443622.USD","LU1979441026.SGD","LU2491050154.USD","IE0002141913.USD","IE00BJJMRX11.SGD","LU0058720904.USD","LU0432979614.USD","LU2357305700.SGD","LU2462591350.SGD","LU1814569148.SGD","IE00BJT1NW94.SGD","BK4534","OZEM","LU0256863902.USD","LU2089984988.USD","THNR","SG9999015945.SGD","VHT","IE00BJJMRZ35.SGD","LU0158827781.USD","LU1280957306.USD","LU0689472784.USD","LU2168564149.EUR","LU0354030511.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671134942","title":"Novo Nordisk announces retrospective RWE on Ozempic in type 2 diabets","url":"https://stock-news.laohu8.com/highlight/detail?id=2671134942","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671134942?lang=en_us&edition=fundamental","pubTime":"2026-09-29 18:10","pubTimestamp":1790676619,"startTime":"0","endTime":"0","summary":"Novo Nordisk (NVO) announced new retrospective real-world evidence in adults with type 2 diabetes treated with once-weekly semaglutide injection 1 ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novo-nordisk-announces-retrospective-rwe-on-ozempic-in-type-2-diabets-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novo-nordisk-announces-retrospective-rwe-on-ozempic-in-type-2-diabets-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1093756325.SGD","NVOH","LU0154236417.USD","NVOC","BK4007","IE00BKVL7J92.USD","BK4599","OZEM","BK4588","BK4532","PPH","THNR","IE00BZ1G4Q59.USD","NVO","NVOX","LU1093756168.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671218563","title":"Novo Nordisk Strikes Second Licensing Deal Since Frosty Capital-Markets Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2671218563","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671218563?lang=en_us&edition=fundamental","pubTime":"2026-09-29 17:46","pubTimestamp":1790675160,"startTime":"0","endTime":"0","summary":"Danish drugmaker to pay up to $2.6 billion for Chinese obesity pill candidateNovo Nordisk struck a licensing deal.Novo Nordisk on Tuesday struck its second licensing deal since receiving a poor recept","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0359202008.SGD","LU1023057109.AUD","IE00BZ1G4Q59.USD","THNR","600276","IE00BKVL7J92.USD","BK4532","NVOH","LU1093756168.USD","NVOX","BK4585","BK4007","NVO","LU0359201612.USD","NVOC","01276","PPH","OZEM","BK4599","BK4588","BK1191","LU0359201885.HKD","LU0154236417.USD","LU1093756325.SGD","LU2543165471.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671298568","title":"China's Hengrui Inks up to $2.6 Billion Deal with Novo Nordisk for Obesity Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2671298568","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671298568?lang=en_us&edition=fundamental","pubTime":"2026-09-29 13:10","pubTimestamp":1790658607,"startTime":"0","endTime":"0","summary":"Sept 29 (Reuters) - Jiangsu $Hengrui Pharmaceuticals(01276)$, China's largest drugmaker by ‌market value, said on Tuesday it will license global rights to ⁠its weight-management drug HRS-1596 to...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nL4N45L0BV:1","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"China's Hengrui Inks up to $2.6 Billion Deal with Novo Nordisk for Obesity Drug","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0405327494.USD","LU2488822045.USD","LU0405327148.USD","LU1064130708.USD","BK0028","LU2097828557.USD","01276","600276","LU1655091616.SGD","LU1969619763.USD","LU2097828714.EUR","LU2328871848.SGD","BK0239","LU1997245094.SGD","LU1580142542.USD","NVOH","LU2097828805.USD","BK0183","LU1820825898.SGD","LU1146622755.USD","LU1997245177.USD","LU2289578879.USD","LU1064131003.USD","NVOX","LU1997244956.HKD","LU2097828474.EUR","LU2148510915.USD","LU2580892789.USD","BK0188","NVO","LU2580892862.HKD","LU1255011170.USD","LU1328615791.USD","LU2097828631.EUR","LU2495084118.USD","LU1781817850.SGD","BK0060","BK0012","NVOC","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107831327","title":"Hengrui Pharma and Novo Nordisk Sign Licensing Agreement for HRS-1596 Project","url":"https://stock-news.laohu8.com/highlight/detail?id=1107831327","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107831327?lang=en_us&edition=fundamental","pubTime":"2026-09-29 12:49","pubTimestamp":1790657347,"startTime":"0","endTime":"0","summary":"Hengrui Pharma (600276.SH) announced that the company has entered into an agreement with Novo Nordisk A/S to license its potential once-weekly oral GLP-1 and GIP dual receptor agonist HRS-1596 to...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2097828631.EUR","LU0405327494.USD","LU1064130708.USD","LU1969619763.USD","LU2328871848.SGD","LU1146622755.USD","LU2148510915.USD","BK0183","LU1093756168.USD","LU1997245094.SGD","NVOH","BK0239","LU1655091616.SGD","LU2097828557.USD","BK4599","LU1093756325.SGD","LU1328615791.USD","01276","LU1781817850.SGD","NVO","NVOC","BK0028","BK4585","LU1064131003.USD","LU2097828474.EUR","LU1820825898.SGD","BK4588","OZEM","LU1997245177.USD","BK0196","LU0405327148.USD","BK0188","BK4007","LU1580142542.USD","THNR","BK0060","LU2289578879.USD","LU2488822045.USD","LU1997244956.HKD","LU1255011170.USD","LU2495084118.USD","LU2097828714.EUR","LU2580892789.USD","IE00BZ1G4Q59.USD","BK4532","BK0012","LU2097828805.USD","LU2580892862.HKD","NVOX","LU0154236417.USD","IE00BKVL7J92.USD","PPH","600276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671250134","title":"Option traders moderately bearish in Novo Nordisk with shares down 0.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2671250134","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671250134?lang=en_us&edition=fundamental","pubTime":"2026-09-29 04:30","pubTimestamp":1790627411,"startTime":"0","endTime":"0","summary":"Option traders moderately bearish in Novo Nordisk (NVO), with shares down 8c near $38.72. Options volume roughly in line with average with 78k cont...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/option-traders-moderately-bearish-in-novo-nordisk-with-shares-down-0-22-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/option-traders-moderately-bearish-in-novo-nordisk-with-shares-down-0-22-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BKVL7J92.USD","NVOH","IE00BZ1G4Q59.USD","LU0154236417.USD","NVO","THNR","LU1093756325.SGD","BK4007","BK4532","LU1093756168.USD","OZEM","BK4585","PPH","NVOC","BK4599","NVOX","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}]}}